Karin F.
- Country
- Germany
- Department
- N/A
Research Overview
- Efficacy and Safety Assessment of Budesonide, Glycopyrronium, and Formoterol Fumarate MDI in Severe Asthma Uncontrolled by Standard Therapy
- Efficacy and Safety Evaluation of AZD4604 in Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Data & Insights
Has run more than one trial at 14 of 210 partner sites.
Specializations
Asthma Therapeutics
Focused on the treatment of moderate‑to‑severe asthma that remains uncontrolled despite high‑dose inhaled therapy.
- Inhaled corticosteroid/long‑acting bronchodilator combinations
- Triple therapy with budesonide, glycopyrronium, and formoterol
- Novel biologic agents targeting airway inflammation
Research emphasizes improving lung function and reducing exacerbation frequency.
Chronic Obstructive Pulmonary Disease
Investigates therapeutic options for COPD aimed at decreasing exacerbations and enhancing quality of life.
- Long‑acting muscarinic antagonists combined with inhaled corticosteroids
- Anti‑IL‑33 biologics for inflammation modulation
- Optimized inhaler delivery systems
Efforts target sustained symptom control and prevention of disease progression.
Lipid‑Lowering Strategies
Dedicated to advancing treatment of hypercholesterolemia and related lipid disorders.
- PCSK9 inhibition for LDL‑C reduction
- Comparative efficacy of bempedoic acid versus novel agents
- Combination lipid‑lowering regimens with statins and ezetimibe
Studies aim to achieve guideline‑recommended LDL‑C targets across diverse patient populations.
Cardiovascular Disease & Atherosclerosis
Explores interventions for patients with atherosclerotic cardiovascular disease and broader cardiovascular risk.
- Lipoprotein(a) lowering with antisense therapies
- Risk reduction of major adverse cardiovascular events
- Integration of lipid‑targeted treatments into standard of care
Focus is on mitigating cardiovascular morbidity and mortality through targeted molecular approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.